Fenwick’s Julia Forbess Talks Biotech Investment and Financing Trends
USPTO and EPO Examiners Discuss Key Considerations for Filing Effective Precision Medicine and Bioinformatics Applications in the US and Europe
Digital Health Companies May Find a Faster Path to Market Under the FDA’s Digital Health Plan
Martin Shkreli Convicted on Three of Eight Counts of Securities Fraud
A More Consistent USPTO Approach to Patent Eligibility
Biosimilars: Solicitor General Recommends Granting Certiorari in Amgen v. Sandoz
Will the Supreme Court Review Whether FDA-Mandated Bioequivalence Testing to Maintain Approval Falls Within the § 271(e)(1) Safe Harbor?
Federal Circuit: A Biosimilar Applicant Must Provide Notice of Intent to Market a Biosimilar Product, No Exceptions
Biosimilars: Supreme Court Calls for Solicitor General’s Views in Amgen v. Sandoz
Connect: Email
Firm/Org